{"data":[{"accessionNo":"0001493152-26-049273","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value","eventDate":"2026-10-22","reportingPerson":"Trails Edge Capital Partners, LP","reportingCik":null,"personType":"IA,PN","sharesOwned":2803761,"percentOfClass":5.2,"filedAt":"2026-10-29","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001493152-26-049273","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value","eventDate":"2026-10-22","reportingPerson":"Ortav Yehudai","reportingCik":null,"personType":"IN","sharesOwned":2803761,"percentOfClass":5.2,"filedAt":"2026-10-29","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001493152-26-049273","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value","eventDate":"2026-10-22","reportingPerson":"Trails Edge Biotechnology Master Fund, LP","reportingCik":null,"personType":"PN","sharesOwned":2803761,"percentOfClass":5.2,"filedAt":"2026-10-29","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001172661-26-003475","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001534120","issuerName":"AVALO THERAPEUTICS, INC.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value","eventDate":"2026-06-30","reportingPerson":"Deep Track Capital, LP","reportingCik":null,"personType":"IA,OO","sharesOwned":3610000,"percentOfClass":6.87,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001172661-26-003475","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001534120","issuerName":"AVALO THERAPEUTICS, INC.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value","eventDate":"2026-06-30","reportingPerson":"Deep Track Biotechnology Master Fund, Ltd.","reportingCik":null,"personType":"CO","sharesOwned":3610000,"percentOfClass":6.87,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001172661-26-003475","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001534120","issuerName":"AVALO THERAPEUTICS, INC.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value","eventDate":"2026-06-30","reportingPerson":"David Kroin","reportingCik":null,"personType":"HC,IN","sharesOwned":3610000,"percentOfClass":6.87,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001231919-26-000918","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"RA Capital Healthcare Fund, L.P.","reportingCik":null,"personType":"PN","sharesOwned":3483099,"percentOfClass":6.3,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001231919-26-000918","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"Rajeev Shah","reportingCik":null,"personType":"HC,IN","sharesOwned":3483099,"percentOfClass":6.3,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001231919-26-000918","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"Peter Kolchinsky","reportingCik":null,"personType":"HC,IN","sharesOwned":3483099,"percentOfClass":6.3,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001231919-26-000918","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"RA Capital Management, L.P.","reportingCik":null,"personType":"IA,PN","sharesOwned":3483099,"percentOfClass":6.3,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001727492-26-000021","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Caligan Partners LP","reportingCik":null,"personType":"IA,PN","sharesOwned":3163866,"percentOfClass":5.9,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001727492-26-000021","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"David Johnson","reportingCik":null,"personType":"HC,IN","sharesOwned":3163866,"percentOfClass":5.9,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000921895-26-002164","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"BVF PARTNERS L P/IL","reportingCik":null,"personType":"IA,PN","sharesOwned":2801545,"percentOfClass":5.3,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000921895-26-002164","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"BVF INC/IL","reportingCik":null,"personType":"CO","sharesOwned":2801545,"percentOfClass":5.3,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000921895-26-002164","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"LAMPERT MARK N","reportingCik":null,"personType":"IN","sharesOwned":2801545,"percentOfClass":5.3,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000921895-26-002164","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"BVF GP HOLDINGS LLC","reportingCik":null,"personType":"OO","sharesOwned":2574007,"percentOfClass":4.8,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000902664-26-003460","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Behzad Aghazadeh","reportingCik":null,"personType":"HC,IN","sharesOwned":2333333,"percentOfClass":4.44,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000902664-26-003460","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Avoro Capital Advisors LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":2333333,"percentOfClass":4.44,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001104659-26-097285","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001534120","issuerName":"AVALO THERAPEUTICS, INC.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value","eventDate":"2026-06-30","reportingPerson":"Wilmot B. Harkey","reportingCik":null,"personType":"HC","sharesOwned":1862250,"percentOfClass":3.54,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001104659-26-097285","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001534120","issuerName":"AVALO THERAPEUTICS, INC.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value","eventDate":"2026-06-30","reportingPerson":"Nantahala Capital Management, LLC","reportingCik":null,"personType":"IA","sharesOwned":1862250,"percentOfClass":3.54,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001104659-26-097285","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001534120","issuerName":"AVALO THERAPEUTICS, INC.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value","eventDate":"2026-06-30","reportingPerson":"Daniel Mack","reportingCik":null,"personType":"HC","sharesOwned":1862250,"percentOfClass":3.54,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000921895-26-002164","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"BVF I GP LLC","reportingCik":null,"personType":"OO","sharesOwned":1466153,"percentOfClass":2.8,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000921895-26-002164","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"BIOTECHNOLOGY VALUE FUND L P","reportingCik":null,"personType":"PN","sharesOwned":1466153,"percentOfClass":2.8,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000921895-26-002164","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"BVF II GP LLC","reportingCik":null,"personType":"OO","sharesOwned":1107854,"percentOfClass":2.1,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000921895-26-002164","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"BIOTECHNOLOGY VALUE FUND II LP","reportingCik":null,"personType":"PN","sharesOwned":1107854,"percentOfClass":2.1,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000921895-26-002164","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"BVF Partners OS Ltd.","reportingCik":null,"personType":"CO","sharesOwned":185010,"percentOfClass":0.4,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000921895-26-002164","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"Biotechnology Value Trading Fund OS LP","reportingCik":null,"personType":"PN","sharesOwned":185010,"percentOfClass":0.4,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001897612-26-000606","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001534120","issuerName":"AVALO THERAPEUTICS INC","ticker":"AVTX","cusip":"05338F306","securityClass":"COMMON STOCK","eventDate":"2026-06-30","reportingPerson":"T. Rowe Price Investment Management, Inc.","reportingCik":null,"personType":"IA","sharesOwned":3670,"percentOfClass":0,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001011438-26-000509","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"Affinity Asset Advisors, LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":2900000,"percentOfClass":5.5,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001011438-26-000509","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"Michael Cho","reportingCik":null,"personType":"IN,HC","sharesOwned":2900000,"percentOfClass":5.5,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000315066-26-002249","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001534120","issuerName":"AVALO THERAPEUTICS INC","ticker":"AVTX","cusip":"05338F306","securityClass":"COMMON STOCK","eventDate":"2026-07-31","reportingPerson":"FMR LLC","reportingCik":null,"personType":"HC","sharesOwned":5737966,"percentOfClass":10.8,"filedAt":"2026-08-07","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000315066-26-002249","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001534120","issuerName":"AVALO THERAPEUTICS INC","ticker":"AVTX","cusip":"05338F306","securityClass":"COMMON STOCK","eventDate":"2026-07-31","reportingPerson":"Abigail P. Johnson","reportingCik":null,"personType":"IN","sharesOwned":5737966,"percentOfClass":10.8,"filedAt":"2026-08-07","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000093751-26-000415","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"AVALO THERAPEUTICS INC","ticker":"AVTX","cusip":"05338F306","securityClass":"COMMON STOCK","eventDate":"2026-06-30","reportingPerson":"STATE STREET CORPORATION","reportingCik":null,"personType":"HC","sharesOwned":2889287,"percentOfClass":5.5,"filedAt":"2026-08-07","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000315066-26-001940","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001534120","issuerName":"AVALO THERAPEUTICS INC","ticker":"AVTX","cusip":"05338F306","securityClass":"COMMON STOCK","eventDate":"2026-06-30","reportingPerson":"FMR LLC","reportingCik":null,"personType":"HC","sharesOwned":5100216,"percentOfClass":9.7,"filedAt":"2026-08-06","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000315066-26-001940","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001534120","issuerName":"AVALO THERAPEUTICS INC","ticker":"AVTX","cusip":"05338F306","securityClass":"COMMON STOCK","eventDate":"2026-06-30","reportingPerson":"Abigail P. Johnson","reportingCik":null,"personType":"IN","sharesOwned":5100216,"percentOfClass":9.7,"filedAt":"2026-08-06","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0002012383-26-002194","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"AVALO THERAPEUTICS INC","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"BlackRock, Inc.","reportingCik":null,"personType":"HC","sharesOwned":3415731,"percentOfClass":6.5,"filedAt":"2026-07-27","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001104659-26-080836","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Millennium Group Management LLC","reportingCik":null,"personType":"OO","sharesOwned":9857,"percentOfClass":0,"filedAt":"2026-07-06","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001104659-26-080836","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Millennium Management LLC","reportingCik":null,"personType":"OO","sharesOwned":9857,"percentOfClass":0,"filedAt":"2026-07-06","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001104659-26-080836","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Israel A. Englander","reportingCik":null,"personType":"IN","sharesOwned":9857,"percentOfClass":0,"filedAt":"2026-07-06","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001831942-26-000029","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value","eventDate":"2026-06-11","reportingPerson":"Michael Kramarz","reportingCik":null,"personType":"HC,IN","sharesOwned":5721109,"percentOfClass":9.9,"filedAt":"2026-06-18","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001831942-26-000029","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value","eventDate":"2026-06-11","reportingPerson":"Robert Egen Atkinson","reportingCik":null,"personType":"HC,IN","sharesOwned":5721109,"percentOfClass":9.9,"filedAt":"2026-06-18","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001831942-26-000029","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value","eventDate":"2026-06-11","reportingPerson":"Commodore Capital Master LP","reportingCik":null,"personType":"PN","sharesOwned":5721109,"percentOfClass":9.9,"filedAt":"2026-06-18","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001831942-26-000029","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value","eventDate":"2026-06-11","reportingPerson":"Commodore Capital LP","reportingCik":null,"personType":"IA,PN","sharesOwned":5721109,"percentOfClass":9.9,"filedAt":"2026-06-18","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000315066-26-001408","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001534120","issuerName":"AVALO THERAPEUTICS INC","ticker":"AVTX","cusip":"05338F306","securityClass":"COMMON STOCK","eventDate":"2026-05-29","reportingPerson":"Abigail P. Johnson","reportingCik":null,"personType":"IN","sharesOwned":3188401,"percentOfClass":6.1,"filedAt":"2026-06-05","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000315066-26-001408","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001534120","issuerName":"AVALO THERAPEUTICS INC","ticker":"AVTX","cusip":"05338F306","securityClass":"COMMON STOCK","eventDate":"2026-05-29","reportingPerson":"FMR LLC","reportingCik":null,"personType":"HC","sharesOwned":3188401,"percentOfClass":6.1,"filedAt":"2026-06-05","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001172661-26-002447","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value","eventDate":"2026-05-22","reportingPerson":"David Kroin","reportingCik":null,"personType":"HC,IN","sharesOwned":3055027,"percentOfClass":5.81,"filedAt":"2026-05-29","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001172661-26-002447","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value","eventDate":"2026-05-22","reportingPerson":"Deep Track Biotechnology Master Fund, Ltd.","reportingCik":null,"personType":"CO","sharesOwned":3055027,"percentOfClass":5.81,"filedAt":"2026-05-29","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001172661-26-002447","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value","eventDate":"2026-05-22","reportingPerson":"Deep Track Capital, LP","reportingCik":null,"personType":"IA,OO","sharesOwned":3055027,"percentOfClass":5.81,"filedAt":"2026-05-29","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000919574-26-003702","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-05-22","reportingPerson":"Steven A. Cohen","reportingCik":null,"personType":"IN","sharesOwned":2710817,"percentOfClass":5.2,"filedAt":"2026-05-26","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000919574-26-003702","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-05-22","reportingPerson":"Point72 Capital Advisors, Inc.","reportingCik":null,"personType":"CO","sharesOwned":2710817,"percentOfClass":5.2,"filedAt":"2026-05-26","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000919574-26-003702","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-05-22","reportingPerson":"Point72 Asset Management, L.P.","reportingCik":null,"personType":"PN","sharesOwned":2710817,"percentOfClass":5.2,"filedAt":"2026-05-26","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000921895-26-001385","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-31","reportingPerson":"BVF PARTNERS L P/IL","reportingCik":null,"personType":"IA,PN","sharesOwned":2347845,"percentOfClass":9.99,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000921895-26-001385","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-31","reportingPerson":"BVF INC/IL","reportingCik":null,"personType":"CO","sharesOwned":2347845,"percentOfClass":9.99,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000921895-26-001385","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-31","reportingPerson":"LAMPERT MARK N","reportingCik":null,"personType":"IN","sharesOwned":2347845,"percentOfClass":9.99,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001346824-26-000147","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-31","reportingPerson":"Rajeev Shah","reportingCik":null,"personType":"HC,IN","sharesOwned":2455655,"percentOfClass":9.9,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001346824-26-000147","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-31","reportingPerson":"RA Capital Healthcare Fund, L.P.","reportingCik":null,"personType":"PN","sharesOwned":2455655,"percentOfClass":9.9,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001346824-26-000147","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-31","reportingPerson":"Peter Kolchinsky","reportingCik":null,"personType":"HC,IN","sharesOwned":2455655,"percentOfClass":9.9,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001346824-26-000147","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-31","reportingPerson":"RA Capital Management, L.P.","reportingCik":null,"personType":"IA,PN","sharesOwned":2455655,"percentOfClass":9.9,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001897612-26-000487","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"AVALO THERAPEUTICS INC","ticker":"AVTX","cusip":"05338F306","securityClass":"COMMON STOCK","eventDate":"2026-03-31","reportingPerson":"T. Rowe Price Investment Management, Inc.","reportingCik":null,"personType":"IA","sharesOwned":2162684,"percentOfClass":9.5,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000921895-26-001385","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-31","reportingPerson":"BVF GP HOLDINGS LLC","reportingCik":null,"personType":"OO","sharesOwned":2178283,"percentOfClass":9.3,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001727492-26-000008","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Caligan Partners LP","reportingCik":null,"personType":"IA,PN","sharesOwned":1635023,"percentOfClass":7.2,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001727492-26-000008","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"David Johnson","reportingCik":null,"personType":"HC,IN","sharesOwned":1635023,"percentOfClass":7.2,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000902664-26-002462","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Behzad Aghazadeh","reportingCik":null,"personType":"HC,IN","sharesOwned":1410000,"percentOfClass":5.75,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000902664-26-002462","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Avoro Capital Advisors LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":1410000,"percentOfClass":5.75,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000921895-26-001385","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-31","reportingPerson":"BIOTECHNOLOGY VALUE FUND L P","reportingCik":null,"personType":"PN","sharesOwned":1258371,"percentOfClass":5.4,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000921895-26-001385","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-31","reportingPerson":"BVF I GP LLC","reportingCik":null,"personType":"OO","sharesOwned":1258371,"percentOfClass":5.4,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000921895-26-001385","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-31","reportingPerson":"BIOTECHNOLOGY VALUE FUND II LP","reportingCik":null,"personType":"PN","sharesOwned":919912,"percentOfClass":4,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000921895-26-001385","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-31","reportingPerson":"BVF II GP LLC","reportingCik":null,"personType":"OO","sharesOwned":919912,"percentOfClass":4,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000935836-26-000282","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock","eventDate":"2026-03-31","reportingPerson":"Arsani William","reportingCik":null,"personType":"HC,IN","sharesOwned":1675000,"percentOfClass":3.2,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000935836-26-000282","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock","eventDate":"2026-03-31","reportingPerson":"Logos GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":1675000,"percentOfClass":3.2,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000935836-26-000282","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock","eventDate":"2026-03-31","reportingPerson":"Logos Global Master Fund LP","reportingCik":null,"personType":"PN","sharesOwned":1675000,"percentOfClass":3.2,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000935836-26-000282","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock","eventDate":"2026-03-31","reportingPerson":"Logos Global Management GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":1675000,"percentOfClass":3.2,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000935836-26-000282","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock","eventDate":"2026-03-31","reportingPerson":"Logos Global Management LP","reportingCik":null,"personType":"IA,PN","sharesOwned":1675000,"percentOfClass":3.2,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000947871-26-000548","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"OrbiMed Advisors LLC","reportingCik":null,"personType":"IA","sharesOwned":475165,"percentOfClass":2.1,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000921895-26-001385","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-31","reportingPerson":"Biotechnology Value Trading Fund OS LP","reportingCik":null,"personType":"PN","sharesOwned":141562,"percentOfClass":0.6,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000921895-26-001385","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-31","reportingPerson":"BVF Partners OS Ltd.","reportingCik":null,"personType":"CO","sharesOwned":141562,"percentOfClass":0.6,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001011438-26-000312","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-31","reportingPerson":"Michael Cho","reportingCik":null,"personType":"IN,HC","sharesOwned":1340840,"percentOfClass":5.5,"filedAt":"2026-05-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001011438-26-000312","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-31","reportingPerson":"Affinity Asset Advisors, LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":1340840,"percentOfClass":5.5,"filedAt":"2026-05-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001193125-26-220002","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-05-05","reportingPerson":"TCG Crossover GP II, LLC","reportingCik":null,"personType":"OO","sharesOwned":3017120,"percentOfClass":7.9,"filedAt":"2026-05-12","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001193125-26-220002","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-05-05","reportingPerson":"TCG Crossover Fund II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":3017120,"percentOfClass":7.9,"filedAt":"2026-05-12","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001193125-26-220002","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-05-05","reportingPerson":"Chen Yu","reportingCik":null,"personType":"IN","sharesOwned":3017120,"percentOfClass":7.9,"filedAt":"2026-05-12","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000315066-26-001098","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001534120","issuerName":"AVALO THERAPEUTICS INC","ticker":"AVTX","cusip":"05338F306","securityClass":"COMMON STOCK","eventDate":"2026-03-31","reportingPerson":"FMR LLC","reportingCik":null,"personType":"HC","sharesOwned":2879481,"percentOfClass":12.6,"filedAt":"2026-05-06","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000315066-26-001098","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001534120","issuerName":"AVALO THERAPEUTICS INC","ticker":"AVTX","cusip":"05338F306","securityClass":"COMMON STOCK","eventDate":"2026-03-31","reportingPerson":"Abigail P. Johnson","reportingCik":null,"personType":"IN","sharesOwned":2879481,"percentOfClass":12.6,"filedAt":"2026-05-06","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000935836-26-000188","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock","eventDate":"2026-03-26","reportingPerson":"Logos Global Management LP","reportingCik":null,"personType":"IA,PN","sharesOwned":1285000,"percentOfClass":5.6,"filedAt":"2026-04-01","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000935836-26-000188","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock","eventDate":"2026-03-26","reportingPerson":"Logos Global Management GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":1285000,"percentOfClass":5.6,"filedAt":"2026-04-01","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000935836-26-000188","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock","eventDate":"2026-03-26","reportingPerson":"Logos Global Master Fund LP","reportingCik":null,"personType":"PN","sharesOwned":1285000,"percentOfClass":5.6,"filedAt":"2026-04-01","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000935836-26-000188","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock","eventDate":"2026-03-26","reportingPerson":"Logos GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":1285000,"percentOfClass":5.6,"filedAt":"2026-04-01","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000935836-26-000188","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":"05338F306","securityClass":"Common Stock","eventDate":"2026-03-26","reportingPerson":"Arsani William","reportingCik":null,"personType":"HC,IN","sharesOwned":1285000,"percentOfClass":5.6,"filedAt":"2026-04-01","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000315066-26-000651","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"AVALO THERAPEUTICS INC","ticker":"AVTX","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2026-02-27","reportingPerson":"FMR LLC","reportingCik":null,"personType":"HC","sharesOwned":2125819,"percentOfClass":11.5,"filedAt":"2026-03-06","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000315066-26-000651","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"AVALO THERAPEUTICS INC","ticker":"AVTX","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2026-02-27","reportingPerson":"Abigail P. Johnson","reportingCik":null,"personType":"IN","sharesOwned":2125819,"percentOfClass":11.5,"filedAt":"2026-03-06","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001104659-26-019185","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-02-17","reportingPerson":"Millennium Management LLC","reportingCik":null,"personType":"OO","sharesOwned":934429,"percentOfClass":5,"filedAt":"2026-02-24","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001104659-26-019185","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-02-17","reportingPerson":"Millennium Group Management LLC","reportingCik":null,"personType":"OO","sharesOwned":934429,"percentOfClass":5,"filedAt":"2026-02-24","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001104659-26-019185","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-02-17","reportingPerson":"Israel A. Englander","reportingCik":null,"personType":"IN","sharesOwned":934429,"percentOfClass":5,"filedAt":"2026-02-24","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000921895-26-000454","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"BVF PARTNERS L P/IL","reportingCik":null,"personType":"IA,PN","sharesOwned":1904257,"percentOfClass":9.99,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000921895-26-000454","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"LAMPERT MARK N","reportingCik":null,"personType":"IN","sharesOwned":1904257,"percentOfClass":9.99,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000921895-26-000454","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"BVF INC/IL","reportingCik":null,"personType":"CO","sharesOwned":1904257,"percentOfClass":9.99,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001346824-26-000035","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"Peter Kolchinsky","reportingCik":null,"personType":"HC,IN","sharesOwned":1939065,"percentOfClass":9.9,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001346824-26-000035","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"RA Capital Management, L.P.","reportingCik":null,"personType":"IA,PN","sharesOwned":1939065,"percentOfClass":9.9,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001346824-26-000035","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"RA Capital Healthcare Fund, L.P.","reportingCik":null,"personType":"PN","sharesOwned":1939065,"percentOfClass":9.9,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001346824-26-000035","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"Rajeev Shah","reportingCik":null,"personType":"HC,IN","sharesOwned":1939065,"percentOfClass":9.9,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000921895-26-000454","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"BVF GP HOLDINGS LLC","reportingCik":null,"personType":"OO","sharesOwned":1787416,"percentOfClass":9.4,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000921895-26-000454","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"BVF I GP LLC","reportingCik":null,"personType":"OO","sharesOwned":1286909,"percentOfClass":6.8,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000921895-26-000454","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"BIOTECHNOLOGY VALUE FUND L P","reportingCik":null,"personType":"PN","sharesOwned":1286909,"percentOfClass":6.8,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000947871-26-000187","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"OrbiMed Advisors LLC","reportingCik":null,"personType":"IA","sharesOwned":1187300,"percentOfClass":6.4,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001727492-26-000006","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"David Johnson","reportingCik":null,"personType":"IA,PN","sharesOwned":881533,"percentOfClass":4.9,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001727492-26-000006","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Caligan Partners LP","reportingCik":null,"personType":"IA,PN","sharesOwned":881533,"percentOfClass":4.9,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001104659-26-016415","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-02-10","reportingPerson":"Israel A. Englander","reportingCik":null,"personType":"IN","sharesOwned":887274,"percentOfClass":4.8,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001104659-26-016415","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-02-10","reportingPerson":"Millennium Group Management LLC","reportingCik":null,"personType":"OO","sharesOwned":887274,"percentOfClass":4.8,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001104659-26-016415","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-02-10","reportingPerson":"Millennium Management LLC","reportingCik":null,"personType":"OO","sharesOwned":887274,"percentOfClass":4.8,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000902664-26-001147","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Point72 Capital Advisors, Inc.","reportingCik":null,"personType":"CO","sharesOwned":627502,"percentOfClass":3.5,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000902664-26-001147","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Steven A. Cohen","reportingCik":null,"personType":"IN","sharesOwned":627502,"percentOfClass":3.5,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000902664-26-001147","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Point72 Asset Management, L.P.","reportingCik":null,"personType":"PN","sharesOwned":627502,"percentOfClass":3.5,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000921895-26-000454","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"BIOTECHNOLOGY VALUE FUND II LP","reportingCik":null,"personType":"PN","sharesOwned":500507,"percentOfClass":2.7,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000921895-26-000454","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"BVF II GP LLC","reportingCik":null,"personType":"OO","sharesOwned":500507,"percentOfClass":2.7,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001193125-26-052938","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Dmitry Balyasny","reportingCik":null,"personType":"HC,IN","sharesOwned":439312,"percentOfClass":2.42,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001193125-26-052938","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Balyasny Asset Management Holdings LP","reportingCik":null,"personType":"HC,PN","sharesOwned":439312,"percentOfClass":2.42,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001193125-26-052938","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"BAM GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":439312,"percentOfClass":2.42,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001193125-26-052938","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Balyasny Asset Management L.P.","reportingCik":null,"personType":"IA,PN","sharesOwned":439312,"percentOfClass":2.42,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001193125-26-052938","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Dames GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":439312,"percentOfClass":2.42,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000921895-26-000454","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"BVF Partners OS Ltd.","reportingCik":null,"personType":"CO","sharesOwned":97524,"percentOfClass":0.5,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000921895-26-000454","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"Biotechnology Value Trading Fund OS LP","reportingCik":null,"personType":"PN","sharesOwned":97524,"percentOfClass":0.5,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001104659-26-012613","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-02-03","reportingPerson":"Millennium Management LLC","reportingCik":null,"personType":"OO","sharesOwned":906762,"percentOfClass":4.9,"filedAt":"2026-02-10","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001104659-26-012613","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-02-03","reportingPerson":"Millennium Group Management LLC","reportingCik":null,"personType":"OO","sharesOwned":906762,"percentOfClass":4.9,"filedAt":"2026-02-10","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001104659-26-012613","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-02-03","reportingPerson":"Israel A. Englander","reportingCik":null,"personType":"IN","sharesOwned":906762,"percentOfClass":4.9,"filedAt":"2026-02-10","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001104659-26-012459","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Class A Common Stock","eventDate":"2025-12-31","reportingPerson":"SilverArc Capital Management, LLC","reportingCik":null,"personType":"IA","sharesOwned":524436,"percentOfClass":2.83,"filedAt":"2026-02-10","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001104659-26-012459","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Class A Common Stock","eventDate":"2025-12-31","reportingPerson":"Devesh Gandhi","reportingCik":null,"personType":"IN","sharesOwned":524436,"percentOfClass":2.83,"filedAt":"2026-02-10","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001104659-26-009818","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-01-28","reportingPerson":"Millennium Management LLC","reportingCik":null,"personType":"OO","sharesOwned":905798,"percentOfClass":4.9,"filedAt":"2026-02-03","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001104659-26-009818","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-01-28","reportingPerson":"Millennium Group Management LLC","reportingCik":null,"personType":"OO","sharesOwned":905798,"percentOfClass":4.9,"filedAt":"2026-02-03","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001104659-26-009818","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-01-28","reportingPerson":"Israel A. Englander","reportingCik":null,"personType":"IN","sharesOwned":905798,"percentOfClass":4.9,"filedAt":"2026-02-03","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000102909-26-000048","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics Inc","ticker":"AVTX","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"The Vanguard Group","reportingCik":null,"personType":"IA","sharesOwned":804084,"percentOfClass":4.43,"filedAt":"2026-01-30","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001315863-26-000095","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-01-22","reportingPerson":"Affinity Asset Advisors, LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":1051054,"percentOfClass":5.7,"filedAt":"2026-01-29","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001315863-26-000095","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-01-22","reportingPerson":"Michael Cho","reportingCik":null,"personType":"IN,HC","sharesOwned":1051054,"percentOfClass":5.7,"filedAt":"2026-01-29","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000921895-25-003090","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-30","reportingPerson":"BVF PARTNERS L P/IL","reportingCik":null,"personType":"IA,PN","sharesOwned":1458151,"percentOfClass":9.99,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000921895-25-003090","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-30","reportingPerson":"LAMPERT MARK N","reportingCik":null,"personType":"IN","sharesOwned":1458151,"percentOfClass":9.99,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000921895-25-003090","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-30","reportingPerson":"BVF INC/IL","reportingCik":null,"personType":"CO","sharesOwned":1458151,"percentOfClass":9.99,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001231919-25-000484","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-30","reportingPerson":"RA Capital Management, L.P.","reportingCik":null,"personType":"IA,PN","sharesOwned":1386167,"percentOfClass":9.9,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001231919-25-000484","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-30","reportingPerson":"RA Capital Healthcare Fund, L.P.","reportingCik":null,"personType":"PN","sharesOwned":1386167,"percentOfClass":9.9,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001231919-25-000484","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-30","reportingPerson":"Rajeev Shah","reportingCik":null,"personType":"HC,IN","sharesOwned":1386167,"percentOfClass":9.9,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001231919-25-000484","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-30","reportingPerson":"Peter Kolchinsky","reportingCik":null,"personType":"HC,IN","sharesOwned":1386167,"percentOfClass":9.9,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000921895-25-003090","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-30","reportingPerson":"BVF GP HOLDINGS LLC","reportingCik":null,"personType":"OO","sharesOwned":1387389,"percentOfClass":9.5,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001104659-25-112690","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001534120","issuerName":"AVALO THERAPEUTICS, INC.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, $0.001 par value","eventDate":"2025-09-30","reportingPerson":"Wilmot B. Harkey","reportingCik":null,"personType":"HC","sharesOwned":1235000,"percentOfClass":9.39,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001104659-25-112690","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001534120","issuerName":"AVALO THERAPEUTICS, INC.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, $0.001 par value","eventDate":"2025-09-30","reportingPerson":"Nantahala Capital Management, LLC","reportingCik":null,"personType":"IA","sharesOwned":1235000,"percentOfClass":9.39,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001104659-25-112690","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001534120","issuerName":"AVALO THERAPEUTICS, INC.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, $0.001 par value","eventDate":"2025-09-30","reportingPerson":"Daniel Mack","reportingCik":null,"personType":"HC","sharesOwned":1235000,"percentOfClass":9.39,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000902664-25-005012","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-09-30","reportingPerson":"Steven A. Cohen","reportingCik":null,"personType":"IN","sharesOwned":1053983,"percentOfClass":8,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000902664-25-005012","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-09-30","reportingPerson":"Point72 Asset Management, L.P.","reportingCik":null,"personType":"PN","sharesOwned":1053983,"percentOfClass":8,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000902664-25-005012","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-09-30","reportingPerson":"Point72 Capital Advisors, Inc.","reportingCik":null,"personType":"CO","sharesOwned":1053983,"percentOfClass":8,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000902664-25-004971","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-09-30","reportingPerson":"David Johnson","reportingCik":null,"personType":"HC,IN","sharesOwned":833333,"percentOfClass":6.3,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000902664-25-004971","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-09-30","reportingPerson":"Caligan Partners LP","reportingCik":null,"personType":"IA,PN","sharesOwned":833333,"percentOfClass":6.3,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001193125-25-281204","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-09-30","reportingPerson":"Balyasny Asset Management L.P.","reportingCik":null,"personType":"IA,PN","sharesOwned":817436,"percentOfClass":6.22,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001193125-25-281204","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-09-30","reportingPerson":"BAM GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":817436,"percentOfClass":6.22,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001193125-25-281204","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-09-30","reportingPerson":"Dmitry Balyasny","reportingCik":null,"personType":"HC,IN","sharesOwned":817436,"percentOfClass":6.22,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001193125-25-281204","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-09-30","reportingPerson":"Dames GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":817436,"percentOfClass":6.22,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001193125-25-281204","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-09-30","reportingPerson":"Balyasny Asset Management Holdings LP","reportingCik":null,"personType":"HC,PN","sharesOwned":817436,"percentOfClass":6.22,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000921895-25-003090","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-30","reportingPerson":"BVF I GP LLC","reportingCik":null,"personType":"OO","sharesOwned":806414,"percentOfClass":5.5,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000921895-25-003090","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-30","reportingPerson":"BIOTECHNOLOGY VALUE FUND L P","reportingCik":null,"personType":"PN","sharesOwned":806414,"percentOfClass":5.5,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001104659-25-112178","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Class A Common Stock","eventDate":"2025-09-30","reportingPerson":"SilverArc Capital Management, LLC","reportingCik":null,"personType":"IA","sharesOwned":720922,"percentOfClass":5.48,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001104659-25-112178","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Class A Common Stock","eventDate":"2025-09-30","reportingPerson":"Devesh Gandhi","reportingCik":null,"personType":"IN","sharesOwned":720922,"percentOfClass":5.48,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000921895-25-003090","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-30","reportingPerson":"BVF II GP LLC","reportingCik":null,"personType":"OO","sharesOwned":580975,"percentOfClass":4,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000921895-25-003090","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-30","reportingPerson":"BIOTECHNOLOGY VALUE FUND II LP","reportingCik":null,"personType":"PN","sharesOwned":580975,"percentOfClass":4,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001193125-25-283440","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, $0.001 Par Value","eventDate":"2025-09-30","reportingPerson":"Neil Shahrestani","reportingCik":null,"personType":"IN,HC","sharesOwned":711967,"percentOfClass":3.8,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001193125-25-283440","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, $0.001 Par Value","eventDate":"2025-09-30","reportingPerson":"Ikarian Capital, LLC","reportingCik":null,"personType":"IA","sharesOwned":711967,"percentOfClass":3.8,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000921895-25-003090","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-30","reportingPerson":"BVF Partners OS Ltd.","reportingCik":null,"personType":"CO","sharesOwned":40633,"percentOfClass":0.3,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000921895-25-003090","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-30","reportingPerson":"Biotechnology Value Trading Fund OS LP","reportingCik":null,"personType":"PN","sharesOwned":40633,"percentOfClass":0.3,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001172661-25-004822","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, $0.001 par value","eventDate":"2025-09-30","reportingPerson":"Deep Track Biotechnology Master Fund, Ltd.","reportingCik":null,"personType":"CO","sharesOwned":0,"percentOfClass":0,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001172661-25-004822","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, $0.001 par value","eventDate":"2025-09-30","reportingPerson":"Deep Track Capital, LP","reportingCik":null,"personType":"IA,OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001172661-25-004822","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, $0.001 par value","eventDate":"2025-09-30","reportingPerson":"David Kroin","reportingCik":null,"personType":"HC,IN","sharesOwned":0,"percentOfClass":0,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001999371-25-017697","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-09-30","reportingPerson":"Affinity Healthcare Fund, LP","reportingCik":null,"personType":"PN","sharesOwned":1006217,"percentOfClass":7.65,"filedAt":"2025-11-13","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0001999371-25-017697","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics, Inc.","ticker":"AVTX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-09-30","reportingPerson":"Affinity Asset Advisors, LLC","reportingCik":null,"personType":"IA","sharesOwned":1006217,"percentOfClass":7.65,"filedAt":"2025-11-13","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"},{"accessionNo":"0000102909-25-000035","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001534120","issuerName":"Avalo Therapeutics Inc","ticker":"AVTX","cusip":null,"securityClass":"Common Stock","eventDate":"2025-09-30","reportingPerson":"The Vanguard Group","reportingCik":null,"personType":"IA","sharesOwned":692637,"percentOfClass":5.26,"filedAt":"2025-10-30","canonicalUrl":"https://xoomar.com/markets/stocks/avtx"}],"updatedAt":"2026-11-04T01:28:05.897Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/avtx","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}